当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2017年, 第17卷, 第5期, 第352-355页
标题:
一例经皮冠状动脉介入术后血小板减少的病例分析
DOI:
10.5428/pcar20170510
作者:
1. 侯微1(1.第二军医大学长海医院药学部 上海 200433 weiwei821338906@126.com)
2. 2(2.天津市天津医院药学部 天津 300211 )
3. 曹爱霖1(1.第二军医大学长海医院药学部 上海 200433 )
4. 钱皎1(1.第二军医大学长海医院药学部 上海 200433 qianjiaosmmu@163.com)
5. 陈文瑶3(3.第二军医大学长海医院心血管内科 上海 200433 )
6. 倪敏4(4.上海市第十人民医院药学部 上海 200072 )
7. 施燕5(5.同济大学附属东方医院药学部 上海 200120 )
摘要:
摘要  目的:分析1例冠心病病人经皮冠脉介入(PCI)术后出现血小板减少的原因。方法:围绕病人的病史和用药史,分析PCI术后血小板减少的原因。根据国家药品不良反应(ADRs)监测中心制定的关联性评价标准和诺氏(Naranjo)不良反应评估量表,对疑似药品进行评定。结果:通过病史和逐个药品排查,血小板减少疑似由抗血小板药物替格瑞洛所致。停用该药品后病人血小板计数逐渐回升,改用氯吡格雷联合阿司匹林继续双联抗血小板治疗,病人病情好转,顺利出院。结论:本例病人血小板减少疑似由替格瑞洛所致。
欢迎阅读《药学服务与研究》!您是该文第 426 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 侯微1,2,曹爱霖1,钱皎1,陈文瑶3,倪敏4,施燕5. 一例经皮冠状动脉介入术后血小板减少的病例分析[J]. 药学服务与研究. 2017; 17(5): 352-355.
英文著录格式 HOU Wei1,2,CAO AiLin1,QIAN Jiao1,CHEN WenYao3,NI Min4,SHI Yan5. Case analysis of thrombocytopenia in a patient after percutaneous coronary intervention[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(5): 352-355.
参考文献:
1. Amsterdam E A,Wenger N K,Brindis R G,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,130(25): e344-e426.
2. 韩雅玲.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
3. van Vuren A J,de Jong B,Bootsma H P,et al. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis[J]. Neth J Med,2015,73(3):136-138.
4. Mosca M,Neri R,Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years[J]. J Rheumatol,2002,29(11):2345-2349.
5. Bodolay E,Csiki Z,Szekanecz Z,et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease(UCTD)[J]. Clin Exp Rheumatol,2003,21(3):313-320.
6. Antón Vázquez V,Pascual L,Corominas H,et al. Relapsed hydroxychloroquine-induced thrombocytopenia in systemic lupus erythematosus patient[J]. Reumatol Clin,2017,13(5):294-296.
7. 钟刚. 阿司匹林过敏伴血小板减少2例[J]. 四川医学,2013,34(8):1282.
8. Karaku V,Deveci B,Kurtoglu E,et al. Early profound secondary autoimmune thrombocytopenia induced by clopidogrel in a patient with a coronary artery stent[J]. Turk J Haematol,2012,29(1):94-95.
9. Vedes E C,Marques L D,Toscano Rico M C. Severe isolated thrombocytopenia after clopidogrel and pentoxifylline therapy:a case report[J]. J Med Case Rep,2011,5:281.
10. 黄年旭,王鹏. 一例急性冠脉综合征合并血小板减少症患者临床用药分析[J].中国处方药,2015,13(9):31-32.
11. James S,A。kerblom A,Cannon C P,et al.Comparison of ticagrelor,the first reversible oral P2Y12 receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial[J].Am Heart J,2009,157(4):599-605.
12. Gurbel P A,Bliden K P,Butler K,et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study[J]. Circulation,2009,120(25):2577-2585.
13. 王贺阳,苏唏,沈成兴,等.替格瑞洛在急性冠脉综合征患者中应用的安全性和有效性分析[J].中国循证心血管医学杂志,2015,7(4):468-471.
14. 李志华,张亚臣,解玉泉,等.替格瑞洛在行经皮冠状动脉介入治疗的急性冠状动脉综合征患者中的疗效和安全性观察[J].中国介入心脏病学杂志,2015,23(8):446-450.